tiprankstipranks
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
US Market

Mersana Therapeutics Income Statement

Last quarter (Q3 2024), Mersana Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Mersana Therapeutics's net income was $-11.50M. See Mersana Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ 36.85M$ 26.58M$ 43.00K$ 828.00K$ 42.12M
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 1.50M$ 900.00K$ 900.00K$ 1.01M$ 1.25M
EBITDA
$ -166.08M$ -199.96M$ -167.94M$ -86.68M$ -26.95M
Operating Income
$ -170.96M$ -203.77M$ -168.86M$ -88.11M$ -30.20M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -171.67M$ -204.21M$ -170.10M$ -88.05M$ -28.21M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Mersana Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis